GI
CRL icon

GAMMA Investing’s Charles River Laboratories CRL Stock Holding History

GAMMA Investing’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$856K Buy
3,776
+308
+9% +$54.8K 0.03% 446
2026
Q1 		$598K Sell
3,468
-186
-5% -$34.5K 0.03% 507
2025
Q4 		$729K Buy
3,654
+1,213
+50% +$220K 0.04% 406
2025
Q3 		$382K Buy
2,441
+569
+30% +$90.4K 0.02% 605
2025
Q2 		$284K Buy
1,872
+474
+34% +$63.2K 0.02% 696
2025
Q1 		$210K Buy
1,398
+533
+62% +$89.4K 0.02% 738
2024
Q4 		$160K Sell
865
-176
-17% -$33.9K 0.01% 805
2024
Q3 		$205K Buy
1,041
+192
+23% +$39.9K 0.02% 613
2024
Q2 		$175K Buy
849
+412
+94% +$93.4K 0.02% 542
2024
Q1 		$118K Buy
437
+151
+53% +$36.1K 0.02% 582
2023
Q4 		$61.9K Buy
+286
New +$56.2K 0.02% 777

Other funds holding CRL

CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return
CPCPP
Canada Post Corporation Pension Plan Toronto, Canada $2.87B AUM 37.96% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
CCMINC
Cardinal Capital Management Inc (North Carolina) Raleigh, North Carolina $826M AUM 32.06% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GAMMA Investing's CRL Position: Q2 2026 in Review

GAMMA Investing increased its Charles River Laboratories (CRL) stake by 8.9% in Q2 2026, buying an estimated $54.8K and bringing the position to 3,776 shares worth $856K. The position accounts for 0.03% of the portfolio, ranked #446.

GAMMA Investing first reported a position in CRL in Q4 2023 and has held it in 11 quarters since. 82 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • GAMMA Investing held 3,776 shares of Charles River Laboratories worth $856K as of Q2 2026.
  • GAMMA Investing bought 308 Charles River Laboratories shares in Q2 2026, an estimated $54.8K.
  • Charles River Laboratories made up 0.03% of GAMMA Investing's portfolio in Q2 2026, its #446 holding.
  • GAMMA Investing first reported a position in Charles River Laboratories in Q4 2023 and has held it in 11 quarters since.
  • 82 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.